Price · as of 2024-12-31
$97.54
Market cap 26.51B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $160.90 | +64.96% |
| Intrinsic Value(DCF) | $87.14 | -10.66% |
| Graham-Dodd Method(GD) | $76.50 | -21.57% |
| Graham Formula(GF) | $60.40 | -38.08% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.10 | $0.00 | |||
| 2019 | $37.59 | $40.22 | $1.33 | $0.00 | $6.00 |
| 2020 | $101.93 | $136.24 | $148,052.91 | $6.90 | $25.50 |
| 2021 | $133.87 | $1,708.94 | $0.06 | $303.60 | $181,474.60 |
| 2022 | $127.45 | $334.03 | $0.00 | $288.10 | $0.00 |
| 2023 | $91.27 | $165.87 | $69.17 | $119.30 | $0.00 |
| 2024 | $108.78 | $137.48 | $75.47 | $76.50 | $60.40 |
AI valuation
Our deep-learning model estimates BioNTech SE's (BNTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $160.90
- Current price
- $97.54
- AI upside
- +64.96%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$87.14
-10.66% upside
Graham-Dodd
$76.50
-21.57% upside
Graham Formula
$60.40
-38.08% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BNTX | BioNTech SE | $97.54 | 26.51B | +41% | -11% | -22% | -38% | -32.97 | 1.15 | 8.12 | -15.84 | — | 1.23 | 80.32% | -47.77% | -24.18% | -3.42% | -37.96% | -2.98% | 0.01 | -99.86 | 7.45 | 7.26 | 25.90 | -17232.00% | -2796.00% | -10524.00% | -1.09% | 0.08 | -7.20% | 0.00% | 0.00% | 0.00% | -4.42 | -23.77 | 2.11 | 6.28 |
| BIIB | Biogen Inc. | $191.82 | 28.15B | +13% | -50% | -35% | -56% | 21.34 | 1.51 | 2.81 | 9.91 | — | 10.66 | 70.47% | 19.14% | 13.18% | 7.39% | 8.18% | 4.50% | 0.38 | 7.63 | 2.68 | 1.70 | 1.27 | -2109.00% | 139.00% | -1848.00% | 7.43% | 0.66 | 9.68% | 0.00% | 0.00% | 1.14% | 16.36 | 14.98 | 3.13 | 3.23 |
| DXCM | DexCom, Inc. | $73.43 | 28.64B | +15% | -6% | -76% | -33% | 34.42 | 10.48 | 6.18 | 24.22 | 72.96 | 10.86 | 60.10% | 19.56% | 17.94% | 34.50% | 32.99% | 13.04% | 0.51 | — | 1.88 | 1.53 | 0.41 | 4718.00% | 1560.00% | 7079.00% | 3.74% | 0.67 | 50.72% | 0.00% | 0.00% | 6.98% | 30.91 | 26.16 | 6.04 | 6.91 |
| GMAB | Genmab A/S | $29.44 | 18.14B | +21% | -15% | -44% | -6% | 19.14 | 3.16 | 4.95 | 16.85 | — | -5.09 | 91.69% | 33.60% | 25.89% | 16.63% | 16.30% | 9.62% | 0.95 | 20.49 | 2.02 | 2.01 | 2.90 | -1936.00% | 1023.00% | -336.00% | 6.23% | 0.83 | 18.73% | 0.00% | 0.00% | 2.33% | 17.81 | 19.37 | 5.98 | 2.77 |
| INCY | Incyte Corporation | $101.27 | 20.15B | +47% | +302% | -42% | +85% | 15.18 | 3.78 | 3.80 | 9.10 | 0.36 | 3.97 | 91.47% | 26.12% | 25.03% | 29.87% | 69.44% | 20.75% | 0.01 | 553.03 | 3.32 | 3.04 | -1.72 | 417333.00% | 2122.00% | 44387.00% | 6.94% | 0.93 | 90.63% | 0.00% | 0.00% | 7.19% | 11.93 | 11.82 | 3.12 | 8.52 |
| NTRA | Natera, Inc. | $208.04 | 29.01B | -52% | +773% | -99% | — | -92.12 | 14.68 | 10.34 | -113.19 | — | 14.68 | 60.30% | -13.10% | -11.22% | -19.42% | -59.87% | -12.28% | 0.16 | -20.80 | 4.00 | 3.73 | 5.12 | -5952.00% | 5675.00% | -12420.00% | 0.39% | 0.39 | 18.65% | 0.00% | 0.00% | 3.18% | -75.40 | 242.08 | 9.88 | 21.78 |
| PHG | Koninklijke Philips N.V. | $32.00 | 30.68B | +25% | -54% | -95% | -76% | 28.63 | 2.34 | 1.44 | 11.71 | — | -29.02 | 45.18% | 7.98% | 5.02% | 7.80% | 6.50% | 3.20% | 0.74 | 4.28 | 1.32 | 0.84 | 2.00 | -22400.00% | -104.00% | -3406.00% | 3.49% | 0.15 | 5.36% | 1.28% | 36.60% | 1.28% | 21.71 | 34.62 | 1.73 | 2.09 |
| RPRX | Royalty Pharma plc | $46.21 | 19.8B | +84% | -35% | -81% | -50% | 15.48 | 3.17 | 8.62 | 17.62 | 64.14 | 3.69 | 100.00% | 65.58% | 32.42% | 19.73% | 11.31% | 7.00% | 1.38 | 5.07 | 0.97 | 2.39 | 5.09 | 2414.00% | 506.00% | -1008.00% | 12.14% | 3.91 | 18.06% | 1.84% | 28.60% | 7.83% | 18.48 | 11.57 | 12.12 | 1.79 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| TEVA | Teva Pharmaceutical Indus… | $33.86 | 38.83B | +22% | -53% | — | -55% | 27.36 | 4.91 | 2.25 | 16.76 | — | -3.27 | 51.79% | 12.50% | 8.17% | 21.35% | 10.30% | 3.54% | 2.20 | 2.35 | 1.04 | 0.54 | 4.40 | -18276.00% | 431.00% | 5327.00% | 2.96% | 0.12 | 5.48% | 0.00% | 0.00% | 2.46% | 24.40 | 45.84 | 3.05 | 0.85 |
| UTHR | United Therapeutics Corpo… | $503.90 | 22.79B | -28% | -44% | -38% | +9% | 17.05 | 3.21 | 7.15 | 11.66 | 130.50 | 3.26 | 87.92% | 46.89% | 41.94% | 19.71% | 25.78% | 17.51% | 0.00 | 76.54 | 6.60 | 3.40 | -0.86 | 1307.00% | 1061.00% | -369.00% | 4.57% | 2.78 | 23.09% | 0.00% | 0.00% | 5.10% | 14.21 | 20.38 | 6.66 | 20.45 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
- CEO
- Ugur Sahin
- Employees
- 6.77K
- Beta
- 1.51
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($87.14 ÷ $97.54) − 1 = -10.66% (DCF, example).